000 03542nam a22005895i 4500
001 978-3-540-48264-2
003 DE-He213
005 20161121230959.0
007 cr nn 008mamaa
008 100301s2007 gw | s |||| 0|eng d
020 _a9783540482642
_9978-3-540-48264-2
024 7 _a10.1007/978-3-540-48264-2
_2doi
050 4 _aHD28-70
072 7 _aKJMV6
_2bicssc
072 7 _aPDG
_2bicssc
072 7 _aBUS087000
_2bisacsh
082 0 4 _a658.514
_223
100 1 _aBaecker, Philipp N.
_eauthor.
245 1 0 _aReal Options and Intellectual Property
_h[electronic resource] :
_bCapital Budgeting Under Imperfect Patent Protection /
_cby Philipp N. Baecker.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2007.
300 _aX, 282 p. 47 illus.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aLecture Notes in Economics and Mathematical Systems,
_x0075-8442 ;
_v587
505 0 _aPatenting Under Uncertainty -- Patent Protection, the Firm, and the Economy -- Uncertainty, Irreversibility, and Flexibility -- Patent Protection in the Pharmaceutical Industry -- Exogenous Patent Risk -- and Related Work -- Patents as Investment Opportunities -- Patent Risk as Jumps in the Underlying Process -- From Business Shifts to Jump Processes -- Preliminary Conclusion -- Endogenous Patent Risk -- and Related Work -- Patent Risk as an Option to Litigate -- Preliminary Conclusion -- Conclusion.
520 _aOver the last years, due to intensive competition in the knowledge economy, legal aspects surrounding intellectual property (IP) rights - including litigation and settlement - have continuously gained in importance. Correspondingly, professional IP management has become an indispensable element of successful value-based management (VBM) in research-intensive firms. With this text, the author proposes an integrated approach to patent risk and capital budgeting in pharmaceutical research and development (R and D), developing an option-based view (OBV) of imperfect patent protection, which draws upon contingent-claims analysis, stochastic game theory, as well as novel numerical methods. Bridging a widening gap between recent advances in the theory of financial analysis and current challenges faced by pharmaceutical companies, the text re-initiates a discussion about the contribution of quantitative frameworks to value-based R and D management.
650 0 _aBusiness.
650 0 _aManagement.
650 0 _aIndustrial management.
650 0 _aOperations research.
650 0 _aDecision making.
650 0 _aFinance.
650 0 _aEconomics, Mathematical.
650 0 _aEconomic theory.
650 0 _aMacroeconomics.
650 1 4 _aBusiness and Management.
650 2 4 _aInnovation/Technology Management.
650 2 4 _aMacroeconomics/Monetary Economics//Financial Economics.
650 2 4 _aFinance, general.
650 2 4 _aEconomic Theory/Quantitative Economics/Mathematical Methods.
650 2 4 _aQuantitative Finance.
650 2 4 _aOperation Research/Decision Theory.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783540482635
830 0 _aLecture Notes in Economics and Mathematical Systems,
_x0075-8442 ;
_v587
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-540-48264-2
912 _aZDB-2-SBE
950 _aBusiness and Economics (Springer-11643)
999 _c506769
_d506769